{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-21-005577","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.190453+00:00","generated_at":"2026-06-29T22:11:23.263702+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anika Q2 revenue $38.1M (+24% YoY); raises FY revenue growth outlook to 11-14%","bullets":["Net income $6.5M ($0.45 diluted EPS) vs net loss $7.7M in Q2 2020.","Adjusted net income $1.4M ($0.09 diluted EPS); adjusted EBITDA $6.1M.","Joint Preservation and Restoration revenue up 79% to $11.9M; segment now 31% of total.","Company raises FY 2021 revenue growth guidance to 11-14% from prior 10-13%.","First surgical case with WristMotion Total Wrist implant; 510(k) clearance for reverse shoulder system."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-21-005577","json":"https://secwatch.observer/filing/0001171843-21-005577.json","markdown":"https://secwatch.observer/filing/0001171843-21-005577.md","text":"https://secwatch.observer/filing/0001171843-21-005577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184321005577/0001171843-21-005577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184321005577/f8k_080521.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:11:23.263702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}